ContraFect Submits Complete Response to IND Clinical Hold

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ContraFect Submits Complete Response to IND Clinical Hold for CF-301

YONKERS, NY--(Marketwired - Dec 2, 2014) - ContraFect Corporation ( NASDAQ : CFRX ) ( NASDAQ : CFRXW ) ( NASDAQ : CFRXZ ), a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced today that it has submitted a complete response to the U.S. Food and Drug Administration (FDA). The complete response addresses all of the issues identified in the Investigational New Drug Application (IND) clinical hold letter issued by FDA.

The IND is for ContraFect's most advanced program, CF-301, and is for the combination of CF-301 and antibiotics for the treatment of Staphylococcus bacteremia, including infective endocarditis, caused by methicillin-sensitive (MSSA) and methicillin-resistant S. aureus (MRSA). 

Julia P. Gregory, ContraFect's chief executive officer commented, "This submission achieves a very important milestone for ContraFect this year. While FDA will make the ultimate decision regarding whether our clinical trial may proceed, we have addressed all of their questions. CF-301 has the potential to make a major impact on the important unmet needs of treating Staph blood stream infections and addressing the global crisis of drug-resistance."

About CF-301:

CF-301 is a bacteriophage lysin with potent activity against Staph aureus infections. Staph infections occur in both hospital and community settings, and in the U.S. there are approximately 120,000 cases annually of Staph bacteremia (a blood borne infection), which causes approximately 30,000 deaths. Of further concern, drug-resistant strains of Staph are now evolving additional resistance against standard-of-care antibiotics, which may ultimately result in increased number of cases and mortality from Staph bacteremia. CF-301 is a bacteriophage lysin that has the potential to be a first-in-class treatment for Staph bacteremia. CF-301 has specific and rapid bactericidal activity against Staph. Combinations of CF-301 with vancomycin or daptomycin increased survival significantly in animal models of disease when compared to treatment with antibiotics or CF-301 alone. CF-301 targets a conserved region of the cell wall that is vital to bacteria, thus making resistance less likely to develop. When used in combination with standard of care antibiotics, the result is a novel combination therapy that has the potential to combat the high unmet clinical need of S. aureus infections.

About ContraFect:

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.

FORWARD-LOOKING STATEMENTS

This press release contains, and our officers and representatives may make from time to time, "forward-looking statements" within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar references to future periods. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect's control, including those detailed in ContraFect's filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact: Barry Kappel, Ph.D., MBA SVP Business Development Tel: 914-207-2300 E-Mail: Email Contact or visit: www.contrafect.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Small Business Insurance Is a Costly Blind Spot Today

Updated Category News Views 32

A busted pipe, a fender-bender, or one bad fall can turn a promising little company into a very expensive regret. That is the plain-English value in insurance expert Michael Oehrke's overview for HelloNation: small-business insurance is not glamorous, it is not growth marketing, and it is often ignored until the owner is staring at a bill that can chew through years of...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 89

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Vizsla's Panuco Delay Puts Security Ahead of Speed

Updated Category News Views 73

A mine schedule can absorb a calendar slip; the people around a mine cannot be treated like a line item. Vizsla Silver's update on Panuco is therefore not the usual development-company chest thumping. It is a sober admission that security, permitting and site readiness have pushed first silver to the second half of 2028, one year later than the prior H2 2027 target....

Continue Reading
Abbe Lane Estate Puts Jewelry Demand on Full Display

Updated Category News Views 40

Glamour Is Walking Back Into the Auction Room Abbe Lane’s jewelry is not being offered as a vague nostalgia exercise; it is arriving with dates, a setting, and a clear split between two December sales. John Moran Auctioneers will lead with The Estate of Abbe Lane on Wednesday, December 9, 2026, at 10:00 a.m. PST, then follow with its Jewelry & Watches auction on...

Continue Reading
Elijah Craig Uses AI Toasts to Sell a Warmer Pour

Updated Category News Views 129

A Speech Prompt With a Bourbon Label Few things expose holiday nerves faster than a raised glass and a room waiting for somebody to say something memorable. Elijah Craig has decided that awkward little moment is marketing territory, rolling out its Digital Perfect Pour, Perfect Toast Generator for mobile and desktop users ahead of the holiday season. The tool asks for a...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 18

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 192

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 62

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Rescue Dog Wines Puts Holiday Bottles to Work for Dogs

Updated Category News Views 74

A Bottle With a Job Beyond the Table Holiday wine promotions usually arrive wrapped in the same tired ribbon: buy more, save a little, pour it at a party, forget it by January. Rescue Dog Wines is taking a more grounded route. The family-owned Lodi-area winery says it gives 50% of profits to animal rescue organizations, and that commitment is not being dressed up as a...

Continue Reading
Pacific Surfliner Faces Thanksgiving Capacity Test

Updated Category News Views 122

Thanksgiving traffic on Southern California freeways is its own yearly punishment, and the Pacific Surfliner is making a sensible pitch: leave the car parked and let the coast roll past the window. For travelers, that can be a real relief. For anyone watching public transportation, this is also a useful little stress test of whether a busy state-supported rail corridor...

Continue Reading

Top 5 Most Recently Viewed Articles

Main Street Capital Reports Impressive Q2 2025 Financials

Updated Category News Views 326

Main Street's Second Quarter 2025 Financial Performance Main Street Capital Corporation (NYSE: MAIN) recently disclosed its remarkable financial results for the second quarter of 2025. The company reported a net investment income of $88.2 million, which translates to approximately $0.99 per share. Additionally, the distributable net investment income stood at $94.3...

Continue Reading
argenx's Q1 2025 Growth: VYVGART Performance Shines Brightly

Updated Category News Views 463

Q1 2025 Financial Results Unveiled by argenx argenx SE, listed on both Nasdaq and Euronext as ARGX, is making waves in the biotech industry with its recent announcement of first-quarter financial results and a comprehensive business update. CEO Tim Van Hauwermeiren expressed enthusiasm regarding the company's trajectory, focusing on their ambitious "Vision 2030"—a...

Continue Reading
Pennsylvania's Resilient Housing Market: An Overview of Trends

Updated Category News Views 135

Pennsylvania Housing Market Shows Notable Resilience The latest data on the housing market in Pennsylvania highlights an encouraging trend, as home prices have experienced a remarkable increase of 6.5% over the past year. This consistent appreciation indicates a vigorous market, even in the face of fluctuating economic conditions. Median Home Prices Reach New Heights In...

Continue Reading
Yum China's Strategy Bolstered by Pizza Hut Buy

Updated Category News Views 129

Yum China's Bold Step Forward Here's a twist in the fast-food market worth chewing on: Yum China has wrapped up its $1.2 billion acquisition of the Pizza Hut brand in Mainland China from Yum! Brands. It's like snagging the keys to a long-coveted car after being the chauffeur for decades. Strategic Flexibility and Margin Growth What's at play? Well, Joey Wat, CEO of Yum...

Continue Reading
Insightful Overview of NCC Group plc's Recent Trading Activity

Updated Category News Views 88

Understanding Recent Trading Activities of NCC Group plc In the fast-paced world of finance, keeping an eye on trading activities can offer invaluable insights. One company that has recently been under the spotlight is NCC Group plc. The trading revelations come from public disclosures made under Rule 8.5, indicating vital movements in their securities. Key Information...

Continue Reading